PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System

Inclusion criteria

• Age 18-75 years
• Patients eligible for elective percutaneous coronary intervention
• Understand and voluntarily sign the informed consent form

Exclusion criteria

The lesion-related exclusion criteria:

• More than 1 stent was planned to deploy in culprit lesion
• In-stent restenosis
• Bifurcation lesion with proposed double stent implantation
• The length of the reference vessel segment proximal or distal to the lesion was less than 5mm
• The length of the implanted stent was larger than 33mm
• The diameter of reference vessel was less than 2 mm or larger than 4 mm
• Lesions were in left main or ostium of right coronary artery
• The distance between either end of the lesion and the lateral branches larger than 2 mm in diameter was less than 5 mm
• Angiography revealed thrombosis in culprit vessel
• Severely calcified lesions or tortuous coronary arteries
• Decreased blood flow (thrombolysis in myocardial infarction score ≤ 2)

Patients-level exclusion criteria:

• Breastfeeding or pregnant women, the subject (or his partner) who had a pregnancy plan during the trial or within 6 months after the end of the trial, and subject who did not agree to use contraception during the trial
• Participants who had withdrawn from other clinical studies within 3 months or are participating in other clinical trials
• Acute myocardial infarction occurred within one week prior to screening
• Cardiac troponin I or cardiac troponin T levels exceed the upper limit of normal reference values within 72 hours of procedure and were of clinical significance
• Renal insufficiency with creatinine > 200μmol/L
• Unsuitable for coronary artery bypass grafting (CABG)
• Unsuitable for percutaneous coronary intervention;
• Coronary spasm
• Chronic total occlusion or subtotal occlusion
• Severe hemodynamic disturbances or shock
• History of CABG
• Coagulation is abnormal and clinically significant
• Severe heart failure (NYHA III, IV or Left ventricular ejection fraction < 30%)
• History of contrast allergy
• Multi-vessel disease
• Chemotherapy or planned chemotherapy
• Investigators consider unsuitable for participants selected for this study